Health Decisions will forecast the future of molecular testing at the CED 2010 Biotech Conference.
Health Decisions is pleased to present an exploration of how adaptive research techniques can facilitate major growth in personalized medicine—one of the most important entrepreneurial and venture opportunities in drug development—at the CED 2010 Biotech Conference February 22-23 in Raleigh.
The panel session, titled Opportunities in Personalized Medicine, will cover the implications of the industry’s rapid shift toward molecular and genomic testing and how entrepreneurs, investors, and drug development veterans can leverage these changes to make smart business decisions and improve global health.
Health Decisions CEO Dr. Michael Rosenberg will discuss these opportunities from a clinical research perspective, accompanied by an expert panel that includes Patrick F. Terry, co-founder of Genomic Health, and Linda Harpole, VP of Global Health Outcomes at GlaxoSmithKline, both of whom will present their specialized points of view on personalized medicine.
Opportunities in Personalized Medicine takes place Tuesday, February 23 from 11:45 – 1:00 p.m. EST at the Raleigh Convention Center.
“A big obstacle to pursuing personalized medicine is that smaller, more individualized populations can seem financially unattractive compared to the huge blockbuster patient pools to which investors have grown accustomed. Applying adaptive principles to study design as well as day-to-day operations presents an immediate promise of dramatically faster, more efficient development pathways. When these small trials for individualized treatments accrue less waste, they suddenly become less risky, more viable investment targets.”
Dr. Michael Rosenberg
President and CEO
For more information including a preview of The Agile Approach to Adaptive Research, please contact Courtney Cleaves, Marketing Manager at firstname.lastname@example.org.